ECM Weekly (10 Aug 2019) - 9F, Huali University, AllHome, Topsports

544 Views10 Aug 2019 13:58
SUMMARY

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for upcoming IPOs.

Happy belated birthday to Singapore!

Capital markets in Asia have been fairly quiet. We have two new filings in Hong Kong, Venus Medtech and Poly Property Development, to keep us busy for the time being. This week, we penned down our thoughts on Huali University Group (HUG HK) which we heard is launching its IPO this month.

We also shared our two-part report of 1H 2019 analytics on Hong Kong IPOs.

In India, however, the two upcoming IPOs are not looking up based on their respective subscription rate. Spandana Sphoorty Financial (SSFL IN) was only 1.05x covered while Sterling & Wilson Solar (SWSL IN) did not get enough demand for its book. The latter's institutional tranche was only subscribed 1.02x, the high-net-worth investor tranche 89% and the retail portion 30%.

In the US, AMTD International (HKIB US)'s debut was strong despite of the corporate governance issues that we have pointed out earlier. We think that the float is tightly held as shown through the poor liquidity after its debut.

9F Inc (JFG US) launched its bookbuild on Friday and Ke Yan, CFA, FRM has already covered the IPO in:

Accuracy Rate:

Our overall accuracy rate is 72.4% for IPOs and 64.4% for Placements

(Performance measurement criteria is explained at the end of the note)

New IPO filings this week

  • Venus Medtech (Hangzhou) (Hong Kong, ~US$300m)
  • Poly Property Development (Hong Kong, ~US$500m)

Below is a snippet of our IPO tool showing upcoming events for the next week. The IPO tool is designed to provide readers with timely information on all IPO related events (Book open/closing, listing, initiation, lock-up expiry, etc) for all the deals that we have worked on. You can access the tool here or through the tools menu.

Source: Aequitas Research, Smartkarma

News on Upcoming IPOs

Analysis on Upcoming IPOs

NameInsight
Hong Kong
Alibaba

Alibaba IPO/Secondary Listing - The Real IPO Only Begins on the 11th Day Post Listing

Alphamab

Alphamab (康宁杰瑞) IPO: Strong R&D Capability and Innovative Platforms

AscentageAscentage Pharma (亚盛医药) IPO: Too Early for an IPO
Ascentage

Ascentage Pharma (亚盛医药) IPO: Updates and Thoughts on HQP1351 (3rd Gen Bcr-Abl TKI)

Ant FinancialAnt Financial IPO Early Thought: Understand Fintech Empire, Growth & Risk Factors
ByteDance

ByteDance (字节跳动) IPO: How Jinri Toutiao Paves The Way for a Bigger Empire (Part 1)

ByteDance

ByteDance (字节跳动) IPO: Tiktok the No.1 Short Video App for a Good Reason (Part 2)

Clarity

Clarity Medical (清晰医疗) IPO: Proxy to HK SMILE Surgery Demand

China Feihe

China Feihe (中国飞鹤) IPO: New Numbers, New Red Flag, and Demographic Risk

Helenbergh

Helenbergh (海伦堡) Early Thoughts - The Usual Red Flag - Related Party Transactions

Home Credit

Home Credit Pre-IPO (Part I) - The Positives - Lots to Like

Home Credit

Home Credit Pre-IPO (Part II) - The Negatives - A Lot More to Dislike

Huali

Huali University (华立大学) IPO Early Thoughts - Risks Abound

Hut Chi-Med

Hutchison-China Med (和黄医药) H-Share Listing: MNC Partnerships Endorsed Its R&D Capabilities

JS Global

JS Global Lifestyle (JS 环球生活) Early Thoughts - Declaring US$470m Dividend Before IPO

MicuRxMicuRx Pharma (盟科医药) IPO: Betting on Single Drug in the Not so Attractive Antibiotic Segment
Renrui

Renrui Human Resources (人瑞人才) Pre-IPO Review - Riding on China's Unicorns

SH Henlius

Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio

SH Henlius

Shanghai Henlius (复宏汉霖) IPO: Valuation of Four Biosimilars

SinoMab

SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy

TaslyTasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters
TopsportsTopsports International Holdings Pre-IPO - Performing Well but All Proceeds Will Likely Go to Belle
TopsportsTopsports Pre-IPO - Quick Take - Nike & Adidas Data Throws up Some Interesting Nuggets
TopsportsTopsports Pre-IPO - Way Ahead of Its Peer on Most Counts
TOT BioTOT Biopharm (东曜药业) IPO: An Unimpressive Pipeline
TubatuTubatu Group Pre-IPO - Performing Better than Qeeka but Growing Much Slower, US$1bn a Stretch
TubatuTubatu Group Pre-IPO - Online -> Online + Offline -> Online -> ?
India
ASKASK Investment Managers Pre-IPO - Riding on a Wave of Wealth
Aakash EduAakash Education Pre-IPO - Fast Growth in an Attractive Sector
Anmol IndAnmol Industries Pre-IPO Quick Take - No Growth, Generous Payments to Founders
Bharat Hotels

Bharat Hotels Pre-IPO - Catching up with Peers

CMS InfoCMS Info Systems Pre-IPO - When a PE Sells to Another PE... Only One Gets the Timing Right
Crystal CropCrystal Crop Protection Pre-IPO - DRHP Raises More Questions than in Answers
Flemingo Flemingo Travel Retail Pre-IPO - Its a Different Business in Every Country
Emami CemEmami Cement Pre-IPO - Still in Ramp Up Phase but Emami Shares Pledge Might Lead to an Early IPO
NSENSE IPO Preview- Not Only Fast..its Risky and Expensive
NSENational Stock Exchange Pre-IPO Review - Bigger, Better, Stronger but a Little Too Fast for Some
MazagonMazagon Dock IPO Preview: A Monopoly Submarine Yard in India with Captive Navy Spending
Mrs. BectorMrs. Bectors Food Specialities Pre-IPO Quick Take - Sales for Its Main Segment Have Been Sta

Lodha

Lodha Developers Pre-IPO - Second Time Lucky but Not Really that Much Affordable
LodhaLodha Developers IPO: Presence in Affordable Segment Saves Lodha the Blushes in a Sluggish Mkt
Penna CemPenna Cement - Aggressive Expansion Plans Even Though Past Performance Has Been Tepid
PNB MetPNB Metlife Pre-IPO Quick Take - Doesn't Stack up Well Versus Its Larger Peers
SterlingSterling and Wilson Solar Pre-IPO - Potentially India's Largest IPO This Year - Ain't No Sunshine
Malaysia
QSRQSR Brands Pre-IPO - As Healthy as Fast Food
The U.S
CloudMindsCloudMinds Inc Early Thoughts - Still Nascent
MetenMeten International Edu (美联国际教育) Early Thoughts - Unclear Strategies
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
x